Showing results (201-210 of 226) with videos related to
Sort By:
Pageof 23
Journal of the National Cancer Institute|December 22, 2020
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma PatientsSimone de Vries, Michael Schaapveld, Cécile P M Janus, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 17, 2009
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0Ronald Boellaard, Mike J O'Doherty, Wolfgang A Weber, et al.Journal of the National Cancer Institute|April 6, 2026
Predicting long-term absolute risk of lung cancer in Hodgkin lymphoma patientsShahin Roshani, Naomi B Boekel, Flora E Van Leeuwen, et al.The Lancet. Oncology|February 4, 2021
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trialPeter Borchmann, Annette Plütschow, Carsten Kobe, et al.Clinical Lymphoma, Myeloma & Leukemia|September 8, 2021
Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma SubtypesRene-Olivier Casasnovas, George Follows, Josee M Zijlstra, et al.Journal of Hematology & Oncology|July 17, 2021
Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL studyMarie Maerevoet, Josee M Zijlstra, George Follows, et al.Journal of Extracellular Vesicles|July 23, 2021
Extracellular vesicle miRNA predict FDG-PET status in patients with classical Hodgkin LymphomaEsther E E Drees, Margaretha G M Roemer, Nils J Groenewegen, et al.Lancet (London, England)|October 25, 2017
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupPeter Borchmann, Helen Goergen, Carsten Kobe, et al.Lancet (London, England)|December 26, 2014
Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trialKarolin Behringer, Helen Goergen, Felicitas Hitz, et al.The New England Journal of Medicine|August 10, 2012
Treatment of older patients with mantle-cell lymphomaH C Kluin-Nelemans, E Hoster, O Hermine, et al.Pageof 23